Literature DB >> 2543281

Pharmacokinetics and tissue penetration of fluconazole in rabbits.

T J Walsh1, G Foulds, P A Pizzo.   

Abstract

Fluconazole is a new bis-triazole antifungal compound which has in vivo and in vitro activity against Candida spp. and Cryptococcus neoformans and excellent penetration into cerebrospinal fluid. However, little is known about the penetration of fluconazole into tissue sites other than cerebrospinal fluid. We therefore studied by high-pressure liquid chromatography the penetration of fluconazole into nine different tissue sites at times of peak and trough concentrations in plasma in rabbits. Fluconazole penetrated into all tissue sites. Tissue/plasma concentration ratios were greater at time of trough concentrations in plasma than at times of peak concentrations in plasma. The finding that fluconazole penetrated into target organs commonly infected by Candida spp. and C. neoformans further supports the therapeutic potential of fluconazole for disseminated candidiasis or cryptococcosis in immunocompromised hosts.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543281      PMCID: PMC172461          DOI: 10.1128/AAC.33.4.467

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Cryptococcal meningitis and fluconazole.

Authors:  B Dupont; E Drouhet
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

Review 2.  Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation.

Authors:  T J Walsh; P A Pizzo
Journal:  Annu Rev Microbiol       Date:  1988       Impact factor: 15.500

3.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

Authors:  C A Arndt; T J Walsh; C L McCully; F M Balis; P A Pizzo; D G Poplack
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

4.  Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B.

Authors:  W R Byrne; C P Wajszczuk
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

5.  Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits.

Authors:  J R Perfect; D T Durack
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

6.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

Review 7.  Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy.

Authors:  J E Edwards; R I Lehrer; E R Stiehm; T J Fischer; L S Young
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

8.  Cryptococcemia.

Authors:  J R Perfect; D T Durack; H A Gallis
Journal:  Medicine (Baltimore)       Date:  1983-03       Impact factor: 1.889

Review 9.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

10.  Fluconazole penetration into cerebrospinal fluid in humans.

Authors:  G Foulds; D R Brennan; C Wajszczuk; A Catanzaro; D C Garg; W Knopf; M Rinaldi; D J Weidler
Journal:  J Clin Pharmacol       Date:  1988-04       Impact factor: 3.126

View more
  23 in total

1.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Candiduria: When and How to Treat It.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

3.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

4.  Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Bo Bo Win Maung; Robert S Mansbach; Michael R Hodges; Malcolm A Finkelman; Karen Joy Shaw; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

5.  Fluconazole therapy of candidal native valve endocarditis.

Authors:  E Roupie; J Y Darmon; L Brochard; M Saada; N Rekik; C Brun-Buisson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-05       Impact factor: 3.267

6.  Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.

Authors:  T J Walsh; C Lester-McCully; M G Rinaldi; J E Wallace; F M Balis; J W Lee; P A Pizzo; D G Poplack
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Penetration of oral fluconazole into gynecological tissues.

Authors:  H Mikamo; K Kawazoe; Y Sato; K Izumi; T Ito; K Ito; T Tamaya
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

8.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

9.  Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.

Authors:  A Louie; Q F Liu; G L Drusano; W Liu; M Mayers; E Anaissie; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

Authors:  A J Fischman; N M Alpert; E Livni; S Ray; I Sinclair; R J Callahan; J A Correia; D Webb; H W Strauss; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.